Glaukos Free Cash Flow 2014-2024 | GKOS
- Glaukos free cash flow for the quarter ending September 30, 2024 was -66.35, a year-over-year.
- Glaukos free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- Glaukos annual free cash flow for 2023 was $-0.078B, a 23.43% increase from 2022.
- Glaukos annual free cash flow for 2022 was $-0.063B, a 173.89% increase from 2021.
- Glaukos annual free cash flow for 2021 was $-0.023B, a 22.89% decline from 2020.
Glaukos Annual Free Cash Flow | |
---|---|
2023 | -78.01 |
2022 | -63.20 |
2021 | -23.07 |
2020 | -29.92 |
2019 | -5.09 |
2018 | 8.55 |
2017 | 19.78 |
2016 | 6.03 |
2015 | -3.07 |
2014 | -7.98 |
2013 | -14.16 |
Glaukos Quarterly Free Cash Flow | |
---|---|
2024-09-30 | -66.35 |
2024-06-30 | -55.32 |
2024-03-31 | -34.84 |
2023-12-31 | -78.01 |
2023-09-30 | -63.13 |
2023-06-30 | -51.60 |
2023-03-31 | -37.67 |
2022-12-31 | -63.20 |
2022-09-30 | -50.90 |
2022-06-30 | -18.34 |
2022-03-31 | 3.23 |
2021-12-31 | -23.07 |
2021-09-30 | -9.10 |
2021-06-30 | -16.97 |
2021-03-31 | -13.00 |
2020-12-31 | -29.92 |
2020-09-30 | -38.38 |
2020-06-30 | -27.53 |
2020-03-31 | -13.88 |
2019-12-31 | -5.09 |
2019-09-30 | 0.29 |
2019-06-30 | 4.29 |
2019-03-31 | -0.44 |
2018-12-31 | 8.55 |
2018-09-30 | -1.00 |
2018-06-30 | -4.63 |
2018-03-31 | -7.70 |
2017-12-31 | 19.78 |
2017-09-30 | 9.18 |
2017-06-30 | 4.57 |
2017-03-31 | 1.57 |
2016-12-31 | 6.03 |
2016-09-30 | 4.80 |
2016-06-30 | 3.88 |
2016-03-31 | -1.31 |
2015-12-31 | -3.07 |
2015-09-30 | -2.12 |
2015-06-30 | -1.38 |
2015-03-31 | -1.25 |
2014-12-31 | -7.96 |
2014-09-30 | -6.19 |
2014-06-30 | -6.13 |
2014-03-31 | -4.85 |
2013-12-31 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Instruments Manufacturing | $7.919B | $0.315B |
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Thermo Fisher Scientific (TMO) | United States | $206.837B | 25.23 |
Intuitive Surgical (ISRG) | United States | $191.293B | 100.01 |
Alcon (ALC) | Switzerland | $42.858B | 28.68 |
Edwards Lifesciences (EW) | United States | $38.815B | 24.65 |
IQVIA Holdings (IQV) | United States | $38.763B | 21.36 |
IDEXX Laboratories (IDXX) | United States | $34.892B | 41.09 |
DexCom (DXCM) | United States | $29.037B | 43.73 |
Waters (WAT) | United States | $22.907B | 33.87 |
STERIS (STE) | Ireland | $21.985B | 25.31 |
SONOVA HOLDING (SONVY) | Switzerland | $21.643B | 0.00 |
Hologic (HOLX) | United States | $18.526B | 19.55 |
Sysmex ADR (SSMXY) | Japan | $12.594B | 39.49 |
Fresenius Medical Care AG KGaA (FMS) | Germany | $12.447B | 12.78 |
Globus Medical (GMED) | United States | $11.296B | 28.77 |
Teleflex (TFX) | United States | $9.083B | 14.49 |
Penumbra (PEN) | United States | $9.066B | 88.81 |
Masimo (MASI) | United States | $8.612B | 41.67 |
PROCEPT BioRobotics (PRCT) | United States | $4.986B | 0.00 |
Integer Holdings (ITGR) | United States | $4.592B | 26.02 |
TransMedics (TMDX) | United States | $3.068B | 97.25 |
Inari Medical (NARI) | United States | $3.003B | 0.00 |
Veracyte (VCYT) | United States | $2.964B | 88.93 |
LivaNova (LIVN) | United Kingdom | $2.878B | 16.61 |
Nihon Kohden (NHNKY) | Japan | $2.557B | 19.42 |
Elekta AB (EKTAY) | Sweden | $2.252B | 18.35 |
Tandem Diabetes Care (TNDM) | United States | $2.043B | 0.00 |
Integra LifeSciences Holdings (IART) | United States | $1.914B | 10.00 |
RxSight (RXST) | United States | $1.832B | 0.00 |
Alphatec Holdings (ATEC) | United States | $1.316B | 0.00 |
Artivion (AORT) | United States | $1.162B | 77.03 |
OPKO Health (OPK) | United States | $1.099B | 0.00 |
Pulse Biosciences (PLSE) | United States | $1.091B | 0.00 |
AVANOS MEDICAL, INC (AVNS) | United States | $0.915B | 15.55 |
ORTHOFIX MEDICAL INC (OFIX) | United States | $0.735B | 0.00 |
IRadimed (IRMD) | United States | $0.722B | 39.01 |
SiBone (SIBN) | United States | $0.652B | 0.00 |
Paragon 28 (FNA) | United States | $0.627B | 0.00 |
Mesa Laboratories (MLAB) | United States | $0.610B | 14.39 |
Pacific Biosciences Of California (PACB) | United States | $0.601B | 0.00 |
AxoGen (AXGN) | United States | $0.584B | 0.00 |
OrthoPediatrics (KIDS) | United States | $0.582B | 0.00 |
Treace Medical Concepts (TMCI) | United States | $0.501B | 0.00 |
CVRx (CVRX) | United States | $0.383B | 0.00 |
Semler Scientific (SMLR) | United States | $0.383B | 25.71 |
Tactile Systems Technology (TCMD) | United States | $0.378B | 20.45 |
Delcath Systems (DCTH) | United States | $0.310B | 0.00 |
ClearPoint Neuro (CLPT) | United States | $0.307B | 0.00 |
AngioDynamics (ANGO) | United States | $0.290B | 0.00 |
Inogen (INGN) | United States | $0.249B | 0.00 |
Sight Sciences (SGHT) | United States | $0.215B | 0.00 |
NeuroPace (NPCE) | United States | $0.208B | 0.00 |
Accuray (ARAY) | United States | $0.192B | 0.00 |
Nevro (NVRO) | United States | $0.189B | 0.00 |
Atossa Genetics (ATOS) | United States | $0.189B | 0.00 |
Alpha Tau Medical (DRTS) | Israel | $0.157B | 0.00 |
KORU Medical Systems (KRMD) | United States | $0.136B | 0.00 |
Sensus Healthcare (SRTS) | United States | $0.117B | 17.44 |
Spectral Diagnostics (EDTXF) | Canada | $0.114B | 0.00 |
908 Devices (MASS) | United States | $0.101B | 0.00 |
EDAP TMS S.A (EDAP) | France | $0.098B | 0.00 |
LENSAR (LNSR) | United States | $0.082B | 0.00 |
Monogram Orthopaedics (MGRM) | United States | $0.077B | 0.00 |
WORK Medical Technology Group (WOK) | China | $0.077B | 0.00 |
Covalon Technologies (CVALF) | Canada | $0.073B | 0.00 |
Hyperfine (HYPR) | United States | $0.068B | 0.00 |
Vicarious Surgical (RBOT) | United States | $0.066B | 0.00 |
EnVVeno Medical (NVNO) | United States | $0.061B | 0.00 |
InspireMD (NSPR) | Israel | $0.059B | 0.00 |
Lucid Diagnostics (LUCD) | United States | $0.054B | 0.00 |
Rapid Micro Biosystems (RPID) | United States | $0.054B | 0.00 |
Accelerate Diagnostics (AXDX) | United States | $0.049B | 0.00 |
Envoy Medical (COCH) | United States | $0.041B | 0.00 |
Biosig Technologies (BSGM) | United States | $0.034B | 0.00 |
Adagio Medical Holdings (ADGM) | United States | $0.032B | 0.00 |
Precision Optics (POCI) | United States | $0.031B | 0.00 |
DarioHealth (DRIO) | United States | $0.029B | 0.00 |
Spectral AI (MDAI) | United States | $0.025B | 0.00 |
Neuronetics (STIM) | United States | $0.021B | 0.00 |
NexGel (NXGL) | United States | $0.020B | 0.00 |
Baird Medical Investment Holdings (BDMD) | $0.019B | 0.00 | |
Microbot Medical (MBOT) | United States | $0.017B | 0.00 |
Ekso Bionics Holdings (EKSO) | United States | $0.017B | 0.00 |
Inspira Technologies OXY B.H.N (IINN) | Israel | $0.017B | 0.00 |
Aspira Women's Health (AWH) | United States | $0.013B | 0.00 |
Autonomix Medical (AMIX) | United States | $0.012B | 0.00 |
PAVmed (PAVM) | United States | $0.012B | 0.00 |
T2 Biosystems (TTOO) | United States | $0.011B | 0.00 |
QT Imaging Holdings (QTI) | United States | $0.010B | 0.00 |
Pixie Dust Technologies (PXDT) | Japan | $0.007B | 0.00 |
Check-Cap (CHEK) | Israel | $0.005B | 0.00 |
Nuwellis (NUWE) | United States | $0.004B | 0.00 |
ENDRA Life Sciences (NDRA) | United States | $0.003B | 0.00 |
ReShape Lifesciences (RSLS) | United States | $0.003B | 0.00 |
Venus Concept (VERO) | Canada | $0.003B | 0.00 |
Helius Medical Technologies (HSDT) | United States | $0.002B | 0.00 |
Nanovibronix (NAOV) | United States | $0.002B | 0.00 |
Avinger (AVGR) | United States | $0.002B | 0.00 |
Bluejay Diagnostics (BJDX) | United States | $0.002B | 0.00 |
SINTX TECHNOLOGIES, INC (SINT) | United States | $0.002B | 0.00 |
Tenon Medical (TNON) | United States | $0.002B | 0.00 |
Longview Acquisition II (LGV) | United States | $0.000B | 0.00 |
Spinal Elements Holdings (SPEL) | United States | $0.000B | 0.00 |